Emricasan (approved for the treatment of non-alcoholic steatohepatitis cirrhosis) as an apoptosis inhibitor, Rilonacept (used for the treatment of cryopyrin-associated periodic syndromes), Canakinumab (for the treatment of systemic juvenile idiopathic arthritis, active Still’s disease) as inhibitors or antibodies neutralizing IL-1β, or Anakinra (used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still’s disease) as an IL-1R antagonist are currently used. This evidence concerns the gene NLRP3 and systemic-onset juvenile idiopathic arthritis.